Most
of the current efforts
in drug discovery are devoted to the
design of molecules able to mitigate side effects by concentrating
the biological action in the targeted tissue. One promising strategy
is photodynamic therapy, which is based on the in situ generation of reactive singlet oxygen upon radiation exposure. However,
such an approach requires the use of an efficient photosensitizer.
This contribution deals with the optical properties of an Ir(III)
complex, [Ir(pbz)2(N^N)] (pbz = 2-phenylbenzimidazole;
N^N = methyl 1-butyl-2-pyridyl-benzimidazole-5-carboxylate), which
has recently been shown to exhort a strong photoactivity, but still
needs further improvements to reach clinical applications. We performed
density functional theory calculations at the M06, PBE0, ωB97xD,
and CAM-B3LYP levels to predict the impact of introducing electron
donor–acceptor groups into the nature of the lowest excited
states. The simulations performed demonstrate that the presence of
a NH2 at the pbz ligand and a NO2 group at the
N^N ligand yield a bathochromic shift of absorption spectrum. We report
the most sensitive positions to tune the optical signatures of this
family of complexes.